Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CARA |
---|---|---|
09:32 ET | 774 | 0.6889 |
09:36 ET | 2001 | 0.682499 |
09:39 ET | 7100 | 0.68 |
09:43 ET | 100 | 0.67965 |
09:45 ET | 500 | 0.677 |
09:50 ET | 9952 | 0.6675 |
09:52 ET | 1100 | 0.6697 |
09:56 ET | 1100 | 0.6898 |
09:57 ET | 165 | 0.6701 |
10:01 ET | 200 | 0.686671 |
10:03 ET | 856 | 0.6792 |
10:06 ET | 1000 | 0.671 |
10:12 ET | 1800 | 0.6675 |
10:14 ET | 100 | 0.6799 |
10:19 ET | 3736 | 0.6604 |
10:21 ET | 484 | 0.6799 |
10:30 ET | 100 | 0.6603 |
10:32 ET | 577 | 0.6602 |
10:33 ET | 2200 | 0.6795 |
10:37 ET | 600 | 0.6794 |
10:39 ET | 100 | 0.6604 |
10:42 ET | 100 | 0.6604 |
10:46 ET | 800 | 0.6604 |
10:48 ET | 220 | 0.6791 |
10:53 ET | 100 | 0.6788 |
11:00 ET | 746 | 0.661 |
11:04 ET | 100 | 0.6788 |
11:06 ET | 900 | 0.678699 |
11:08 ET | 100 | 0.662 |
11:09 ET | 100 | 0.662 |
11:11 ET | 395 | 0.6788 |
11:13 ET | 100 | 0.6611 |
11:24 ET | 423 | 0.6689 |
11:26 ET | 7090 | 0.6773 |
11:31 ET | 282 | 0.6689 |
11:33 ET | 100 | 0.6691 |
11:40 ET | 100 | 0.6689 |
11:49 ET | 225 | 0.669 |
11:54 ET | 350 | 0.6771 |
12:03 ET | 800 | 0.67 |
12:09 ET | 611 | 0.677 |
12:12 ET | 644 | 0.6771 |
12:16 ET | 516 | 0.6732 |
12:20 ET | 200 | 0.6774 |
12:34 ET | 2100 | 0.6773 |
12:36 ET | 2100 | 0.6773 |
12:38 ET | 1000 | 0.67375 |
12:39 ET | 100 | 0.6702 |
12:43 ET | 700 | 0.6773 |
12:59 ET | 1700 | 0.6691 |
01:01 ET | 300 | 0.6686 |
01:06 ET | 2300 | 0.661 |
01:08 ET | 8428 | 0.65205 |
01:14 ET | 1249 | 0.65665 |
01:19 ET | 100 | 0.6541 |
01:24 ET | 100 | 0.6541 |
01:26 ET | 1349 | 0.6591 |
01:28 ET | 250 | 0.65877 |
01:32 ET | 100 | 0.6529 |
01:33 ET | 325 | 0.6507 |
01:37 ET | 293 | 0.6504 |
01:39 ET | 3235 | 0.6541 |
01:50 ET | 300 | 0.66 |
02:00 ET | 200 | 0.65 |
02:09 ET | 100 | 0.65 |
02:11 ET | 3869 | 0.659 |
02:13 ET | 551 | 0.65205 |
02:20 ET | 19099 | 0.6429 |
02:22 ET | 100 | 0.641 |
02:24 ET | 792 | 0.64 |
02:27 ET | 1200 | 0.64 |
02:29 ET | 100 | 0.64 |
02:31 ET | 388 | 0.643877 |
02:33 ET | 250 | 0.643759 |
02:38 ET | 400 | 0.6424 |
02:40 ET | 1050 | 0.64005 |
02:42 ET | 1100 | 0.644699 |
02:44 ET | 1100 | 0.6446 |
02:45 ET | 100 | 0.64 |
02:47 ET | 7517 | 0.6446 |
02:49 ET | 200 | 0.64 |
02:54 ET | 100 | 0.64 |
02:58 ET | 600 | 0.64 |
03:02 ET | 200 | 0.64 |
03:05 ET | 200 | 0.6446 |
03:07 ET | 100 | 0.64 |
03:09 ET | 200 | 0.64 |
03:12 ET | 100 | 0.64 |
03:14 ET | 6122 | 0.64 |
03:16 ET | 16799 | 0.635 |
03:18 ET | 1661 | 0.6375 |
03:20 ET | 200 | 0.6352 |
03:21 ET | 200 | 0.635 |
03:23 ET | 2624 | 0.6394 |
03:25 ET | 1839 | 0.6376 |
03:27 ET | 613 | 0.635 |
03:30 ET | 300 | 0.631 |
03:32 ET | 400 | 0.6356 |
03:34 ET | 5803 | 0.6356 |
03:36 ET | 421 | 0.6326 |
03:38 ET | 6253 | 0.6352 |
03:39 ET | 7600 | 0.63985 |
03:41 ET | 436 | 0.639 |
03:43 ET | 900 | 0.6403 |
03:45 ET | 100 | 0.64045 |
03:48 ET | 950 | 0.6375 |
03:50 ET | 1475 | 0.6383 |
03:52 ET | 300 | 0.6355 |
03:54 ET | 9015 | 0.639 |
03:56 ET | 500 | 0.6385 |
03:57 ET | 1004 | 0.6439 |
03:59 ET | 2705 | 0.6421 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cara Therapeutics Inc | 35.5M | -0.3x | --- |
ImmuCell Corp | 33.2M | -9.1x | --- |
Aadi Bioscience Inc | 44.2M | -0.7x | --- |
Turnstone Biologics Corp | 60.4M | -0.8x | --- |
SQZ Biotechnologies Co | 1.3M | 0.0x | --- |
Viaderma Inc | 8.5M | 0.0x | --- |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.5M |
---|---|
Revenue (TTM) | $16.9M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-2.26 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -729.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.